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ABSTRACT: The application of iridium(I) NHC/phosphine
catalysts has delivered highly selective deuteration of indole,
azaindole, and pyrrole N-heterocycles, which represent an
important and relatively underexplored class of labeling substrates.
Common N-protecting groups have been used to selectively direct C−H activation and can be removed under mild conditions
with retention of the deuterium label. The method is exempliﬁed by the labeling of the drug molecule sumatriptan.
Complementary DFT studies have been conducted to facilitate the rationalization of the very good selectivity oﬀered by the mild
and convenient labeling process.
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■ INTRODUCTION
Isotopic labeling plays a key role in the drug discovery process
by oﬀering an unparalleled insight into the metabolic pathways
of a potential drug molecule.1 In recent years, hydrogen isotope
exchange (HIE), via metal-catalyzed C−H activation, has been
widely adopted as a key method for the synthesis of isotopically
labeled compounds, allowing late-stage incorporation of
deuterium or tritium (2H or 3H), thus avoiding the need for
expensive, labeled starting materials.2
Until recently, the industry standard catalyst for HIE was an
Ir(I) complex developed by Crabtree, 13 (Figure 1); however,
there are some drawbacks associated with its use. Speciﬁcally,
complex 1 has limited functional group compatibility, is
thermally unstable, and often has to be used in stoichiometric
or superstoichiometric quantities. Studies within our laboratory
have resulted in the development of a range of HIE catalysts of
the type 2 (Figure 1), bearing a combination of bulky
phosphine and N-heterocyclic carbene ligands.4−13 These
complexes exhibit high activity as deuteration catalysts under
mild reaction conditions, displaying appreciable eﬃciency and
selectivity at low catalyst loadings. Complexes 2 have been
shown to eﬀect HIE directed by a broad range of functional
groups, including a number of heterocyclic systems.4,7,9,11
As privileged structures in both the pharmaceutical and
agrochemical industries, indoles and related N-heterocycles
have received increased attention over the last few decades, and
the indole moiety now represents one of the most important
scaﬀolds in modern drug discovery.14 With regard to the HIE of
indoles15 via metal-catalyzed C−H activation,16,17 previous
work in this area has required elevated temperatures or resulted
in either moderate levels of labeling or labeling at multiple
sites.18−20 Herein, we report our studies which further expand
the scope of our HIE methodology to the indole and pyrrole
classes of N-heterocycles, to deliver a mild, selective, and
preparatively simple labeling method delivering high levels of
deuterium incorporation (Figure 2).
Our previous work has shown that C−H activation with
catalysts 2 usually occurs preferentially via a ﬁve-membered
metallacyclic intermediate (5mmi) over a 6mmi.4,7 We
therefore proposed that common N-protecting groups could
be used as functional handles to direct C−H activation
selectively to the C2 position of indole (Figure 3).21
■ RESULTS AND DISCUSSION
To initiate our studies, indole was protected with a selection of
amide and carbamate protecting groups, giving derivatives 3−6.
These substrates were evaluated under mild HIE conditions (1
atm of D2, DCM, 25 °C, 1 h) with 5 mol % of our developed
catalyst [(COD)Ir(IMes)(PPh3)]PF6 (2a)
4,7 and, for compar-
ison, Crabtree’s catalyst [(COD)Ir(py)(PCy3)]PF6 (1) (Table
1). With N-acetylindole (3), use of catalyst 2a resulted in
labeling exclusively at the C2 position, with an excellent 94%
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Figure 1. Ir(I) catalysts for hydrogen isotope exchange.
Research Article
pubs.acs.org/acscatalysis
© XXXX American Chemical Society 7182 DOI: 10.1021/acscatal.7b02682
ACS Catal. 2017, 7, 7182−7186
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
deuterium incorporation (entry 1). In comparison, under the
same conditions only 22% labeling was observed at C2 with
catalyst 1 (entry 2). With the bulkier directing group in N-
pivaloylindole (4), labeling with 2a was reduced slightly to 82%
(entry 3), but the high levels of labeling could be recovered by
switching to catalyst 2b, which bears a less sterically demanding
phosphine ligand (entry 4). Again, however, Crabtree’s catalyst
1 gave a low 18% incorporation (entry 5). A similar trend was
observed with ethyl carbamate derivative 5, with catalyst 2a
delivering 94% labeling (entry 6), in comparison to only 7%
with 1 (entry 7). With the more hindered tert-butoxy carbamate
6, both 2a and 1 gave only low levels of labeling (entries 8 and
10, respectively), but again, higher levels of deuterium
incorporation could be restored by employing complex 2b
(entry 9).
We next investigated the preference for labeling the
heterocycle versus a competing aromatic site. In this regard,
N-benzoylindole (7) was selected as a suitable substrate since,
in addition to the indole C2 position, the ortho positions of the
benzoyl group can also be accessed via a 5mmi. When catalyst
2a was employed in the labeling of 7, rather remarkable
selectivity was observed for labeling at the C2 position of the
indole over the aromatic ortho sites in the benzoyl group
(Table 2, entry 1). Through tuning of the reaction conditions,
deuterium incorporation at C2 was increased to 80−90%,
maintaining only minimal labeling on the benzoyl group
(entries 2 and 3).
To understand the origins of this notable selectivity, the
reaction was studied computationally, in order to establish the
relative energies of binding and C−H activation for each of the
possible labeling sites. In compounds containing more than one
directing group, the binding energy for each group can play a
key role in determining the selectivity.13a In N-benzoylindole 7,
however, all three potential labeling sites are accessed from the
same directing group. In this case, the relative C−H activation
energies for each bound conformer might be expected to
inﬂuence the selectivity. Figure 4 shows the three potential
energy surfaces (PESs) for C−H activation. At the initial
binding phase, the conformer leading to C7 deuteration is the
lowest in free energy (Grel = 0.0 kcal mol
−1), albeit only
marginally more stable than the conformer for benzoyl
activation (+0.4 kcal mol−1). In contrast, the conformer leading
to activation of the C2 position is signiﬁcantly destabilized
(+4.5 kcal mol−1). However, given that the C2 position is the
preferred labeling site, these energy diﬀerences suggest that the
more stable binding modes are not the most reactive. This
observation is in contrast to previous studies with multiple
directing groups within a substrate, which showed that the
binding mode stability has the ability to directly determine the
labeling selectivity.13a Instead, calculation of the energy barriers
to the respective C−H activations reveals that the free energy
barrier to activation of the C2 position is by far the lowest of
the three processes and is the only exothermic reaction
coordinate of the three. We, therefore, conclude that the higher
kinetic barrier to C−H activation of the C7 and benzoyl
positions is the source of the appreciable labeling selectivity
observed with N-benzoylindole (7). These results are in accord
Figure 2. C−H activation and HIE on indole systems.
Figure 3. Metallacyclic intermediates formed during metal-catalyzed
C−H activation.
Table 1. Deuteration of N-Acylindoles
entry substrate R catalyst D (%)a
1 3 Me 2a 94
2 3 Me 1 22
3 4 tBu 2a 82
4 4 tBu 2b 93
5 4 tBu 1 18
6 5 OEt 2a 94
7 5 OEt 1 7
8 6 OtBu 2a 12
9 6 OtBu 2b 73
10 6 OtBu 1 5
aDeuterium incorporations are an average of two reaction runs.
Table 2. Selective Deuteration of N-Benzoylindole
entry temp (°C) time (h) C2 D (%)a Bz D (%)a
1 25 1 73 2
2 25 24 90 6
3 40 1 80 4
aDeuterium incorporations are an average of two reaction runs.
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with our experimental observations for the labeling of
benzanilide, where two labeling sites are accessed via a single
directing group.4,7 Additionally, in terms of the C−H activation
calculations, the extremely low levels of benzoyl-directed
incorporation are indistinguishable from the lack of C7 labeling
at the semiquantitative levels of the methods employed. The
absolute free energy barriers to C−H activation of the three
possible labeling sites are summarized in Table 3.
Having established an eﬃcient method for the C2 labeling of
acyl-protected indoles, we next explored the use of alternative
modes of direction (Scheme 1). For example, beginning with
substituents at the C3 position of the indole moiety, the
Weinreb amide group in substrate 8 was able to act as a
functional handle, directing labeling to the C2 position with
99% deuterium incorporation. For 3-formylindole (9),
selectivity was observed for deuteration of the C2 over the
formyl position, though with only a moderate 29% incorpo-
ration at C2. When 9 was protected as the ethyl carbamate to
give 10, however, deuteration at the C2 position increased to
97%, with the level of aldehyde labeling remaining low. Turning
to alternative heterocyclic units with acyl direction, for isomeric
N-acetylazaindole substrates 11 and 12, the presence of an
additional nitrogen atom had no negative eﬀects on
coordination, with excellent levels of C2 labeling being
delivered for both substrates. In an attempt to bias the system
toward labeling at C7, N-acetylbenzopyrazole (13) was
subjected to our labeling conditions. In this case, however, no
labeling was observed.
In a further extension of the substrate scope, a range of
substituted pyrroles17d,e,22,23 was subjected to our labeling
conditions (Scheme 2). While the ethyl and tert-butyl
carbamate protected pyrroles 14 and 15 did not mediate
eﬀective levels of labeling, we were pleased to see that acetyl-
Figure 4. Potential energy surfaces (PESs) for C−H activation of the three potential labeling sites of N-benzoylindole (7).
Table 3. Free Energy Barriers for the C−H Activation of N-
Benzoylindole (7)
entry binding conformer ΔG°init
a
ΔG⧧ a ΔG°prod
a
1 C7 0.0 28.0 9.9
2 Bz 0.4 28.7 11.1
3 C2 4.5 20.5 3.2
aAll energies are in kcal mol−1 normalized against the C7 binding
conformer; values were calculated using M06/6-31G* in the gas phase.
Additional details are provided in the Supporting Information.
Scheme 1. Scope of N-Heterocycle Deuteration
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and benzoylpyrroles 16 and 17, respectively, were labeled with
high deuterium incorporation. Further, the corresponding
formylpyrroles 18 and 19 were also labeled eﬃciently, with
no decarbonylation or aldehydic labeling observed.
In order to increase the general utility of these deuteration
protocols, conditions for removal of two of the more eﬀective
directing groups were investigated. Pleasingly, both acetyl and
ethyl carbamate protected indoles 3 and 5, respectively, could
be deprotected under basic conditions to yield C2-deuterated
indole 20 with retention of the deuterium label (Scheme 3).
As a ﬁnal example, and to highlight the application of our
developed methodology in an industrially relevant context, the
deuterium labeling of sumatriptan (21),24 a 5HT-receptor drug
used to treat migraines and cluster headaches, was investigated
(Scheme 4). Ethyl carbamate protection, labeling, and
deprotection reactions proceeded to yield 2-deuterosumatrip-
tan ([2-2H]-21) in a 46% yield over three steps. Importantly, an
excellent 92% deuterium incorporation was obtained, with
negligible isotopic degradation observed during deprotection.
■ CONCLUSIONS
To conclude, we have established a mild and general method
for the C2 deuteration of indole, azaindole, and pyrrole N-
heterocycles. Through the use of common directing groups as
removable functional handles, high levels of deuterium
incorporation have been achieved for a range of substrates.
Notable selectivity for C−H activation via a 5mmi is observed,
and the C2 position can be selectively labeled in the presence of
benzoyl groups. The labeling and subsequent deprotection of
the commercial migraine drug sumatriptan serve to further
highlight the applicability and eﬀectiveness of the developed,
preparatively simple catalytic process for use by pharmaceutical
partners engaged in drug discovery endeavors.
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